Neurocrine Shares Rise on Strong Sales Growth and Positive Institutional Inflows
Neurocrine Biosciences (NBIX) reported first-quarter fiscal 2026 net product sales of over $800 million, driven by a 44% year-over-year increase in INGREZZA. The company also showed strong institutional investor interest and is expected to see continued EPS growth.
Tickers: $NBIX
Topics: biopharmaceutical institutional_investment sales_growth